Inspection of investigational drugs used in clinical trials in France may cover good manufacturing practices (GMP) in the broad sense or for a given clinical trial. These inspections protect the subjects of biomedical research under French law. They are also a validation of quality work and a method of improving future clinical trials. This paper details what a sponsor should expect during an inspection and provides guidelines for proper preparation.
Guideline on the preparation of investigational new drug products (human and animal). Rockville, MD: U.S. Food and Drug Administration; 1991. Center for Drug Evaluation and Research. U.S. Department of Health and Human Services.
2.
Good manufacturing practice for medicinal products in the European Community. Brussels: Commission of the EC; 1989.
3.
Good clinical practice for trials on medicinal products in the European Community. Commission of the EC; 1990:III/3976/88-EN.
4.
Clinical investigations.Proposed establishment of regulations on obligations of sponsors and monitors. Federal Register. September 27, 1977; 496:12–52. U.S. Department of Health, Education and Welfare.
5.
Obligations of clinical investigators of regulated articles.Proposed establishment of regulations. Federal Register. U.S. Department of Health, Education and Welfare, August 8, 1978;352:10–36.
6.
Government order no. 90–872 of 27 September 1990 specifying the implementation conditions of the Law no. 88–1138 of 20 December 1988 (“Journal Officiel” dated 22 December 1988) as amended by the Law no. 90–86 of 23 January 1990 “Journal Officiel” dated 25 January 1990. Law of persons undergoing biomedical research. “Journal Officiel” dated 29 September 1990: 11862–8.
7.
Law no. 88–1138 of 20 December 1988 (“Journal Officiel” dated 22 December 1988) as amended by the Law no. 90–86 of 23 January 1990 (”Journal Officiel” dated 25 January 1990). Law of persons undergoing biomedical research.
8.
HirschAF. Preparation for an FDA sponsor/monitor inspection. Drug Information J.1988;22: 157–9.
9.
WordenLJHolsteinHM. HIMA Regulatory Compliance Manual: FDA Inspections—Before, During and After. Washington, DC: Health Industry Manufacturers Association; 1979. Report #79–1.
10.
ArtigesAPoyE. Audits and inspections of clinical studies. Recent Trends in Clinical Pharmacology. Ed. BoisselJPCaulinCTeuleM. Paris: Colloque INSERM/John Libbey Eurotext Ltd.1991;205:51–70.
11.
TrottmannDMorenasJ. Key points of audit and inspection. SFSTP Pharma. 1989;5: 115–20.
12.
LisookAB. FDA audits of clinical studies: policy and procedure. J Clin Pharmacol.1990;30: 296–302.
13.
SprietADupin-SprietT. Good practice of clinical drug trials. Basel: Karger; 1992:261–75.
14.
Compliance program guidance manual. Bioresearch monitoring-drugs, biologics, veterinary drug products, medical devices and radiological health products. Sponsors, contract research organizations and monitors. Compliance with regulations. Rockville, MD: U.S. Food and Drug Administration; 1988.
15.
Compliance program guidance manual. Bioresearch monitoring-human drugs. Clinical investigators. Rockville, MD: U.S. Food and Drug Administration; 1988.
